BIKTARVY® is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg without present or past evidence of viral resistance to bictegravir or tenofovir. For paediatric patients ≥2 years of age, weighing at least 14 kg to less than 25 kg, the dose is one 30mg/120mg/15mg tablet once daily.